A Phase 3, Open-label Study to Evaluate the Safety of TRV130 in Patients With Acute Pain for Which Parenteral Opioid Therapy is Warranted

Trial Profile

A Phase 3, Open-label Study to Evaluate the Safety of TRV130 in Patients With Acute Pain for Which Parenteral Opioid Therapy is Warranted

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 20 Jul 2017

At a glance

  • Drugs Oliceridine (Primary)
  • Indications Pain; Postoperative pain
  • Focus Adverse reactions; Registrational
  • Acronyms ATHENA-1
  • Sponsors Trevena
  • Most Recent Events

    • 20 Jul 2017 According to a Trevena media release, data from this study will be presented at 2017 Analyst Day.
    • 20 Jul 2017 According to a Trevena media release, based on the data from this study company plans to submit New Drug Application for OLINVOTM (oliceridine injection) is expected in September or October 2017.
    • 20 Jul 2017 Results published in a Trevena media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top